Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
Open Access
- 8 February 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 401
Abstract
The modulation of peroxisome proliferator-activated receptors (PPARs), the superfamily of steroid–thyroid–retinoid nuclear receptors, is expected to induce an amazing crosstalk between energy-demanding organs. Here, we aimed to study the effects of the novel selective PPARα modulator, pemafibrate, on metabolic parameters in patients with dyslipidemia. We retrospectively studied patients who had taken pemafibrate and compared metabolic parameters at baseline with the data at 3, 6 and 12 months after the start of pemafibrate. Serum triglyceride significantly decreased and high-density lipoprotein-cholesterol significantly increased at 3, 6 and 12 months after the start of pemafibrate. Serum aspartate aminotransferase levels significantly decreased at 3 and 6 after the start of pemafibrate as compared with baseline. Serum alanine aminotransferase and gamma-glutamyl transferase significantly decreased and albumin significantly increased after 3, 6 and 12 months. HbA1c levels significantly decreased after 3 months. Further, serum uric acid significantly decreased after 12 months. Such metabolic favorable changes due to pemafibrate were significantly correlated with changes in serum lipids. In conclusion, we observed a significant improvement of liver function, HbA1c and serum uric acid along with an amelioration of dyslipidemia after the start of pemafibrate.Keywords
This publication has 58 references indexed in Scilit:
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonistsCardiovascular Diabetology, 2013
- The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathwaysBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysisAmerican Journal of Therapeutics, 2010
- Harmonizing the Metabolic SyndromeCirculation, 2009
- SLC2A9 Is a High-Capacity Urate Transporter in HumansPLOS Medicine, 2008
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factorClinical Science, 2008
- The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti CohortsPLOS Genetics, 2007
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990
- Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of manAtherosclerosis, 1978